Fact sheet BPR European Biocidal Product Regulation

Akzo Nobel
Surface Chemistry AB
Fact sheet BPR
European Biocidal Product Regulation
Date of issue: 19th November 2014
In Europe the Biocidal Product Directive (98/8/EC, BPD) was in place since May 2000. A part of
the implementation is the evaluation of all existing active substances (active substances already
on the EU market before May 2000) during a transition period. The original transition period was
10 years but this transition period was extended to 2014. New active substances (active
substances not on the EU market before May 2000) do not fall under the transition period but
are only allowed when first registered.
After more than 10 years in practice the BPD was revised. The new Biocidal Product Regulation
(BPR – EU 528/2012) on the use and placing on the market of biocidal products repealed and
replaced the Directive on biocides (98/8/EC) on 1 September 2013. The transition period has
now been extended up to 2024.
Details on this revision/replacement can be found on:
The new regulation increases the protection of health and environment, and it should be more
efficient at the same time, notably through the active involvement of European CHemicals
Agency (ECHA - also in charge of REACH). It will retain the two-step authorization process
brought in by the Directive, whereby active substances are first tested and approved and
included in a Community list (known as the Annex I under the Directive), with subsequent
authorization of the products containing the approved active substance.
Under the BPR the RMS’s (Rapporteur Member States) are now called eCA’s (evaluating
Competent Authorities). An eCA does the initial evaluation and writes the draft CAR (competent
authority report) within 365 days. Draft CAR’s can be discussed with applicant and/or individual
MS and in working groups to solve open issues before they are brought to BPC (Biocidal
Product Committee) for conclusions. According to the Biocidal Products Regulation (BPR) the
opinion on the approval of an active substance has to be submitted by ECHA to the Commission
within 270 days of the receipt of the conclusions of the evaluating Competent Authority (eCA).
An overview of the different steps in this BPR process of the peer review can be found in table1.
Amendments to the BPR were found to be necessary in an early phase and entered into force
on 25 April 2014. The act is titled “Regulation (EU) No 334/2014 of the European Parliament and
of the Council of 11 March 2014 amending Regulation (EU) No 528/2012 concerning the making
available on the market and use of biocidal products, with regard to certain conditions for access
to the market” and is available for download at the following address (the link gives a list of new
legislation but this act starts at p22) : http://eur-lex.europa.eu/legalcontent/EN/TXT/?uri=OJ:L:2014:103:TOC
A consolidated version of the BPR can be found via the following link: http://eurlex.europa.eu/legal-content/EN/TXT/?qid=1409322218709&uri=CELEX:02012R0528-20140425
Date of issue: 19 November 2014
Fact sheet BPR
It combines the three amendments already made to the BPR text in one easy-to-read document:
The extension of the review programme
The amendment of Annex III regarding the need to provide proof of technical
equivalence at product authorization
The BPR revision.
The main consequence of the amended BPR are as follows: The scope of biocidal family
increased slightly, formulators can also notify for Article 95 and the authorities can have up to 3
years to finalize the biocidal product evaluations.
What are the main differences between the Directive and the new Regulation?
The scope has been extended to cover articles and materials treated with biocidal products,
including furniture and textiles. The regulation will also apply to active substances generated in
situ, and to biocidal products used in materials that come into contact with food. But other
products that are sufficiently covered by existing legislation (including food and feed, food and
feed additives and processing aids) are excluded from the scope of the new regulation. Biocidal
products approved under the International Convention for the Control and Management of Ships'
Ballast Water and Sediments are considered as authorized.
The system will become paperless and fully IUCLID based (same software system as for
REACH). The data base system to submit dossiers electronically is called R4BP3. R4BP3 is the
communication tool with ECHA for issues on biocides dossiers. IUCLID can be downloaded from
ECHA for free and access to R4BP3 is possible via ECHA when a REACH-IT account is
generated. Guidance on these tools is also published on the ECHA website.
Under the BPR there will be a possibility for Union Authorization at the ECHA. The deadlines are
laid down in Art 42 of the BPR. To avoid an overload of ECHA a step-wise planning is laid down.
Applicants may apply for Union authorization for biocidal products which have similar conditions
of use across the Union with the exception of biocidal products that contain active substances
that fall under Article 5 and those of Product Types 14, 15, 17, 20 and 21. The Union
authorization may be granted:
(a) from 1 September 2013, to biocidal products containing one or more new active substances
and biocidal products of product-types 1, 3, 4, 5, 18 and 19;
(b) from 1 January 2017, to biocidal products of product-types 2, 6 and 13; and
(c) from 1 January 2020, to biocidal products of all remaining product-types (besides those
Active substance suppliers not having own dossier or Letter of Access will have to phase out by
September 2015. In order to be able to check if suppliers have submitted dossiers under the
BPD/BPR a list is prepared by ECHA with approved suppliers and this list will be regularly
Date of issue: 19 November 2014
Fact sheet BPR
updated. With the amended BPR there are now also possibilities to apply for listing by
formulators of some biocidal products. This possibility is mainly generated for importers of
formulations for which the active substance is not supported by the non-EU manufacturers. The
latest list of approved suppliers can be found on the ECHA website: http://echa.europa.eu/documents/10162/17287015/2014_active_substance_suppliers_en.pdf
Suppliers participating in the review program have to do an Article 95 notification via R4BP3 to
come on this list. We have done this Article 95 notification for all our active substances
evaluated in the review program.
It is now very important for formulators of biocidal products to check if their suppliers are
included in the Article 95 notification list for the product types of interest. If the supplier is not on
the list, this can be an indication that he has not yet started a registration process according to
BPD/BPR. The list is regularly updated by ECHA and will become legally binding from 1st
September 2015. If the active substance supplier is still not on the list beginning September
2015 the formulator is no longer allowed to use the active ingredient from this supplier.
Recently the review regulation is updated. The detailed rules for the Review Programme have
been adapted to the provisions of the BPR in the new Review Programme Regulation (EU) No
1062/2014, which repeals and replaces Commission Regulation (EC) No 1451/2007. Full details
can be found via the following link:
The latest article 95 list mentions CAS numbers and chemical names and the PT’s but does no
longer mention the entry number. Our 4 active substances are included in the article 95
notification list under the full chemical names:
- Alkyl (C12-16) dimethylbenzyl ammonium chloride (ADBAC/BKC (C12-C16)) - Entry number:
671 ; EC number: 270-325-2 CAS number: 68424-85-1,
- Didecyldimethylammonium chloride (DDAC) – Entry number: 397 ; EC number: 230-525-2 ;
CAS number: 7173-51-5,
- Quaternary ammonium compounds, coco alkyltrimethyl, chlorides - Entry number: 635 ;
(ATMAC/TMAC) EC number: 263-038-9 ; CAS number: 61789-18-2
- N-(3-aminopropyl)-N-dodecylpropane-1,3-diamine (Diamine) - Entry number 330; EC number:
219-145-8; CAS number: 2372-82-9.
The name Diamine is given by the Rapporteur Member State Portugal for our Triameen Y12D,
the TMAC entry covers our Arquad C products, the BKC entry covers our Arquad MCB products
and the DDAC entry covers our Arquad 2.10 products. For customers of ours we can make
available a statement on the Art 95 notification for the active substances supported by
AkzoNobel Surface Chemistry AB, upon request. The notifications made can also be found in
the list at the ECHA website.
If a company wants to be able to continue to remain active in the biocides market, it will be a
legal obligation in all member states of interest to have approval for all the formulations with
biocidal claims. In the biocidal product dossier, the access to the active substance dossier will
have to be covered with a Letter of Access from the actual supplier of the active ingredient
(unless the active substance dossier is also owned by the applicant). Details for the Letter of
Access are laid down in Art 61 of the BPR.
An alternative solution can be to try to get a “same biocidal product license” from an approved
product. Details can be found in the same biocidal product regulation:
Date of issue: 19 November 2014
Fact sheet BPR
This will be a cheaper process but the composition / uses will initially have to be exactly the
same as the original approval. After approval the dossier becomes independent and can be
updated via a major change, for instance to add surfactants or to add PT’s assuming sufficient
data is generated to proof efficacy and safe use. The active substance should remain the same.
Recently ECHA has published a practical guide on various topics relevant to the BPR:
Under the BPD/BPR, the application areas are called Product Types (PT). Under the new BPR
there are 22 categories which are listed in Annex V of the BPR. The different PT’s we support for
our active substances are given in Table 2. A detailed description of the PT’s can be found on:
In the beginning of the BPD registration process we had done our utmost to get registration of
groups of quaternary ammonium compounds. Our RMS (Rapporteur Member State) has forced
us to submit separate full dossiers for each active substance CAS number in the different
groups, and this could economically not be justified.
We currently only support
didecyldimethylammonium chloride (CAS number 7173-51-5) in case of the DDAC dossier, C1216-alkyldimethylbenzylammonium chloride (CAS number 68424-85-1) in case of the BKC dossier
and cocoalkyltrimethylammonium chloride (CAS number 61789-18-2) in case of the TMAC
dossier. For simplicity we will remain calling these single substances in this factsheet BKC,
The three quaternary ammonium compounds are being evaluated by Italy. Italy has informed us
that they intend to follow the priority setting made by ECHA to meet the 2024 deadline (see table
below). The evaluation of Triameen Y12D (dodecyldipropylene triamine) CAS no 2372-82-9 is
done by Portugal. Portugal informed us that they intend to come with Competent Authority
Reports for all Product Types supported in one go, but they cannot give an indication when the
draft CAR’s will be made available.
Although a proposal for a decision on inclusion should officially have to be taken by the RMS
within 1 year after accepting our dossiers as complete, unfortunately this did not happen in
To be able to meet the new deadline for the review program of 2024 ECHA has set new
priorities for the different application areas (PT’s) in the new review program.
Existing active
substances for
product types
1st priority list
8, 14, 16, 18, 19, 21
Deadline for
submission of all
draft CARs by
3, 4, 5
2 priority list
Deadline for
ECHA to deliver
its opinions
3 priority list
1, 2
4th priority list
6, 13
5th priority list
7, 9, 10
12,15,17, 22, 23 (new
PT20 under BPR)
6 priority list
7 priority list
Date of issue: 19 November 2014
Fact sheet BPR
Status of our dossiers:
Below an overview can be found of all the different steps (actions) in the evaluation process
under the BPR. The implementation of the BPR has slightly changed the evaluation process and
the system of TM meetings and CA meetings is replaced by a system of WG (Working Group)
and BPC (Biocidal Product Committee) meetings. It is planned that the frequency of meetings
will increase to speed up the process. In the new process the BPC meets about 5 times per year
(instead of 3 times for the previous TM meetings) to discuss the technical issues and decide on
a final version of the CAR (= AR and Conclusions).
PT 8:
For BKC and DDAC there are 2 consortia involved, an US consortium (USQC) and the
European QUAT Consortium (EQC). We as AkzoNobel Surface Chemistry are member of the
In February 2013 the decisions on Annex I inclusion of CAS number 68424-85-1 (BKC) and CAS
number 7173-51-5 (DDAC) for PT 8 became final and the deadline for product dossier
submission for PT8 for all biocidal products on the market using the approved CAS numbers
(independent of the supplier) is now fixed on February 1st 2015. When an extra active ingredient
is included in the product which is not yet approved, then a deadline for BPR dossiers applies of
2 years after the official approval of the last active substance. When the formulation is used for
several PT’s the deadline for BPR is after the approval of the active substance for the last PT. In
the meantime of course the national rules have to be followed.
The official publications for PT8 can be found here:
Our dossiers for BKC and DDAC were discussed and approved during the TM meeting of June
2013. For these 2 substances there are two applicants with approved dossiers (EQC and
USQC). In this situation of multiple applicants the official guidance documents for multiple
dossiers have to be followed. This guidance tells that a combined assessment report and a
combined Listing of Endpoints have to be developed before the inclusion decision is made.
Officially these combined documents should be used for the risk assessment calculations of the
biocidal products. This guidance was not followed by eCA Italy. Unfortunately these combined
documents will not be available before the PT 8 product deadline. EQC was invited for the
November Competent Authority meeting to solve this situation. The EQC chairman (AkzoNobel)
and EQC lawyer attended the CA meeting on November 13th and during this CA meeting an
agreement was made to solve this situation. For the time being both applicants may refer to their
own List of Endpoints for the PT 8 applications. It is expected that Italy will be able to deliver the
combined documents for the BPC meeting in April 2015. When the combined documents are
approved, the eCA’s have to check the submitted PT8 dossiers and have to correct them when
Date of issue: 19 November 2014
Fact sheet BPR
differences are found between the submitted information and the results from the combined
documents. It is not expected that significant differences will be found. This agreement results in
equal and fair treatment of all dossiers submitted for PT8. The deadline for PT8 dossiers for
products based on BKC or DDAC remains 1st of February 2015. The official paper of the
European Commission on this issue can be made available upon request.
For TMAC for PT8 a draft CAR was received in 2010 and comments were submitted in 2010.
We were recently informed that BPC (Biocidal Product Committee) discussion of TMAC dossier
for PT8 is planned for March 2015. eCA Italy will keep us informed if something changes.
(Officially we are in step 10 of the BPR process).
PT 1,2,3,4,10,11,12:
In March 2012, we received the initial draft CAR for PT 1,2,3,4 (disinfection areas) for DDAC for
commenting on availability of confidential information within one month.
In beginning of May 2012 we received the commenting tables for DDAC for PT 1, 2, 3, 4, and we
have delivered our comments within the 90-days commenting period of the BPD. This means for
DDAC for PT1, 2, 3, 4, we are now in step 10 of the BPR process.
For BKC for PT 1,2,3,4 (disinfection areas) we received the commenting table half September
2012 and the 90 days commenting period of the BPD started and deadline for submission was
set on December 10th 2012. The commenting tables for BKC for PT1,2,3 and 4 were submitted
in time. This means we are for BKC for PT 1, 2, 3, 4 in step 10 of the BPR process.
For the other PT’s for BKC (10,11,12) and DDAC (10,11,12) we are still in step 1.
Italy has informed us recently that they intend to follow the priority setting made by ECHA to
meet the 2024 deadline. This will most probably result in different inclusion dates per PT.
For the evaluation of Triameen Y12D (dodecyldipropylene triamine) CAS no 2372-82-9 we are in
action 1 for all PTs applied for. The draft CAR reports for Triameen Y12D for PT 2,3,4,10,11 are
not yet received from Portugal. Portugal informed us recently that they intend to come with
Competent Authority Reports for all Product Types supported in one go, but they cannot give an
indication when the draft CAR’s will be made available.
Since the deadlines are not applied by the authorities, it is difficult / not possible for us to predict
dates for final Union listing for the PT’s supported by us.
Date of issue: 19 November 2014
Fact sheet BPR
List of abbreviations used
Assessment Report
Accredited Stakeholder Organizations
Biocidal Product Committee (the selected technical experts of the MS meet about 5
times per year at ECHA)
Biocidal Product Directive
Biocidal Product Regulation
Competent Authority
Competent Authority Report
CIRCA-BC a portal of collaborative workspace for partners of the European Institutions.
Commission (In the overview COM is used but where relevant to be more specific
also COM-ENV (Directorate General Environment) and COM-JRC (Joint Research
Centre) are used.
evaluating Competent Authority
European Chemicals Agency
European QUAT consortium
Listing of Endpoints
Member State
Member State Competent Authority
not applicable
Product Type (application area)
response to commenting table (consolidated commenting table)
Rapporteur Member State
ECHA secretariat
Technical Meeting (representatives present of all MS)
United States based QUAT Consortium
Due to the implementation of the BPR there is now again a kind of ”transition state”. New active
substance dossiers (not falling under the review program) will be under the responsibility of
ECHA. The existing active substances already under evaluation according to the BPD continue
to be evaluated by those RMS’s / eCA’s that were already responsible for the substances. They
do the evaluation up to the level of draft CAR publication. Instead of moving it then to TM level it
will now be moved to BPC level at ECHA.
For the CAR’s submitted before 1 September 2013 the situation is as follows: A number of
evaluations have been submitted by RMS’s under the BPD. The peer review of these CARs can
be at any stage of the process, as e.g. some of them have gone through the commenting stage
and others have been finalized at the Technical Meetings under the BPD. The decisions on
these active substances will be made according to the BPD, while the decisions on active
substances for which the CAR is submitted after 1 September 2013 will be made according to
the BPR.
The full details of the Standard Operating Working Procedures for the Biocidal Product
committees can be found on the ECHA website:
Date of issue: 19 November 2014
Fact sheet BPR
Table 1: Description of the steps / timelines in the peer review process.
1. Submission of CAR
Submission. The eCA submits the results of the evaluation in the
form of a CAR and an annotated IUCLID dossier. The submission
is done via CIRCABC. In principle, the CAR template provided for
applications under the BPR should be used.
Accordance check. SECR performs a check to verify that the
CAR fulfils the requirements as indicated in under 5.24.
1. Accordance check: pass. The submission is accepted and the
evaluation will proceed to the commenting stage (see 3.
Commenting phase) and to public consultation if relevant (see 2.
Public consultation). The eCA is informed of the result of the
accordance check via R4BP v3.
Accordance check: fail. The CAR and the IUCLID dossier are
returned to the eCA for modifications. The eCA is informed of the
result of the accordance check via R4BP v3.
a. Resubmission. Following a failure in the accordance check,
the eCA will revise and resubmit the CAR, as well as the IUCLID
dossier if necessary.
Responsible actor
(Approximate time
(365 days after
validation of
(14 days)
(at next submission
2. Public consultation
Responsible actor
(Approximate time
These steps are performed only if the eCA proposes the active substance to be a
potential candidate for substitution. For CARs already submitted, public consultation will
be performed before scheduling discussions in WGs.
See for full details the working procedure
Date of issue: 19 November 2014
Fact sheet BPR
3. Commenting phase
Distribution of CAR. SECR distributes the CAR and a
template for commenting to the MSCAs via CIRCABC and to
the applicant via R4BP v3.
Commenting phase. Comments are made available to the
eCA and other MSCAs via CIRCABC using the template for
commenting. The MSCAs upload their comments directly to
CIRCABC, while the applicant sends the comments to SECR
via R4BP v3 and SECR then uploads these comments to
Response to comments table (RCOM). The eCA prepares a
consolidated table including all comments together with the
eCA responses to them. Where possible, during this time the
eCA will verify whether the commenting MSCA/applicant
agrees with the response, and include information on this in
the table. The eCA sends this RCOM to SECR via CIRCABC
and to the applicant using ad hoc communication in R4BP v3.
A separate confidential RCOM is prepared if there are
comments on confidential information.
Distribution of RCOM. SECR makes the RCOM available to
the MSCAs via CIRCABC.
4. Working Group meeting and preparations for this
Responsible actor
(Approximate time
SECR (Without delay)
MSCAs; applicant
(42 days)
(35 days)
(Without delay)
Responsible actor
(Approximate time
WG meets about 5 times a year to discuss open issues –
See for full details the working procedure
5. Ad hoc follow-up
Responsible actor
(Approximate time
These steps are performed only if there are open points following the WG meeting.
See for full details the working procedure
Date of issue: 19 November 2014
Fact sheet BPR
6. Biocidal Products Committee and preparations for this
SECR-eCA dialogue. Immediately following the WG meeting, SECR
and the eCA will start preparations for the BPC meeting. The aim of the
dialogue is to find an agreement on issues related to the BPC opinion.
Updating the CAR. The eCA will begin modifying the CAR (AR and
Conclusions) immediately after the WG discussion, based on the
agreements in the RCOM, WG meeting and ad hoc follow-up where
relevant. The CAR (AR and Conclusions) is submitted to SECR via
Drafting BPC opinion. SECR will draft the BPC opinion in cooperation
with the eCA using the Conclusions section of the CAR, taking into
account the agreements in the RCOM, WG meeting and ad hoc followup where relevant.
Distribution. SECR distributes the updated AR and the draft BPC
opinion to MSCAs via CIRCABC and to the applicant using ad hoc
communication in R4BP3.
BPC meeting. BPC adopts the opinion unless written procedure is
requested (see Rules of Procedure).
The accredited stakeholder organizations (ASO) will be present but do
not have access to documents concerning the substances.
BPC opinion finalization. The BPC opinion is finalized according to the
agreements at the BPC and forwarded to COM (for official inclusion
decision). (According to the Biocidal Products Regulation (BPR) the
opinion on the approval of an active substance has to be submitted by
ECHA to the Commission within 270 days of the receipt of the
conclusions of the evaluating Competent Authority (eCA))
Updating the AR. The eCA provides to SECR via CIRCABC the
updated AR based on the discussions and agreements.
AR distribution. SECR makes the updated AR available to the MSCAs
via CIRCABC and to the applicant using ad hoc communication in R4BP
time limit)
eCA (ending 21
days before the
eCA (21 days
before the BPC
SECR (17 days
before the BPC
SECR (17 days
before the BPC
SECR (21 days)
eCA (42 days)
SECR (Without
Biocidal product phase
Product authorization: Biocidal product
supplier to apply for authorization at country
authority level of the country/countries of
interest for marketing the biocidal product.
Alternatively Union authorization can be
applied for at ECHA.
Max 24 months after official inclusion decision (for
the last active substance falling under the review
program in a biocidal product), the product
dossiers have to be submitted. Authorities have
maximum 36 months to finalize the evaluations.
Date of issue: 19 November 2014
Fact sheet BPR
Table 2
Product Types notified for Art 95 and supported with a registration dossier by
Akzo Nobel Surface Chemistry AB per active substance
Product Type (PT)
Main group I: Disinfectants and general biocidal
1. Human hygiene
2. Disinfectants and algaecide not intended for direct
application on humans or animals (previously
called Private and public health area)
3. Veterinary hygiene
4. Food and feed area
5. Drinking water
Main group II: Preservatives
6. Preservatives for products in storage (previously
called: In can preservatives)
7. Film preservatives
8. Wood preservatives
9. Fiber, leather, rubber and poly-merized material
10. Construction material preservatives (previously
called: Masonry preservatives)
11. Preservatives for liquid cooling and processing
12. Slimicides
13. Working and cutting fluid preservatives (previously
called: Metalworking fluid preservatives)
CAS no:
CAS no:
CAS no:
CAS no:
Main group III: Pest control
14. Rodenticides
15. Avicides
16. Molluscicides, vermicides and products to control
other invertebrates
17. Piscides
18. Insecticides, acaricides and products to control
other arthropods
19.Repellants and attractants
Main group IV: Other biocidal products
20. Control of other vertebrates
21. Antifouling products
22. Embalming and taxidermist fluids
Date of issue: 19 November 2014